

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

HE 20.9210:983/suppl. 7

The University
of Michigan
Pharmacy
Library

499-k-3



SERIAL

REFERENCE
DO NOT WRITE

**CUMULATIVE
SUPPLEMENT 7
AUG'83 - MAR'84**

Pharm.
R1A
300
A653

4th ed.
Suppl. 7



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

THE UNIVERSITY
OF MICHIGAN

JUN 13 1984

MEDICAL
LIBRARY

UNIVERSITY OF MICHIGAN
LIBRARIES

MAY 17 1984

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUGS AND BIOLOGICS

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN
DEPOSITED BY THE
UNITED STATES OF AMERICA

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "List". The cumulative supplements routinely provide updates to two of these Lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol > ADD > to the left of the line on which new information exists. The > ADD > symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DELT (DELETE) to the left of the line containing the overstruck print. The >DELT symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL	OPTOPTICS LABORATORIES	OPTOPTICS LABS
DIV STERI-MED INC	CORP	

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A, refers to the products in the List and Section B, to products in the current cumulative supplement. A new column of data will appear in Section A, each three-month period following July '83. Section A, therefore will provide baseline and quarterly data while Section B, provides monthly activity.

USE OF REPORT

From the data presented under Section B, users should be able to observe such things as (1) newly approved, DESI effective and remarkeeted drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multi-source or single source during each month within the quarter. The report does not reflect category changes from multi-source to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multi-source and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the List composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

<u>CATEGORIES COUNTED</u>	<u>JULY '83 (BASELINE)</u>	<u>OCT '83</u>	<u>JAN '84</u>
DRUG PRODUCTS LISTED	6679	6783	6854
SINGLE SOURCE	1908 (28.6)	1915 (28.2%)	1933 (28.2%)
MULTISOURCE ⁽¹⁾	4771 (71.4)	4868 (71.8%)	4921 (71.8%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)	3939 (57.5%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)	972 (14.2%)
EXCEPTIONS ⁽²⁾	10 (0.1%)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2	8
NUMBER OF APPLICANTS	304	310	312

B. ACTIVITY FOR SUPPLEMENT NUMBER 7

	<u>FEB '84</u>	<u>MAR '84</u>	<u>CUMULATIVE</u>
DRUG PRODUCTS ADDED:	28	41	69
NEWLY APPROVED	28	38	66
DESI EFFECTIVE	0	3	3
REMARKETED	0	0	0
DRUG PRODUCTS REMOVED:	7	10	17
WITHDRAWN APPROVAL	0	0	0
RX TO OTC SWITCH	0	0	0
DISCONTINUED MARKETING	9	10	19
NET GAIN IN DRUG PRODUCTS	21	31	52
SINGLE SOURCE PRODUCTS APPROVED	4	5	9
MULTISOURCE DRUG PRODUCTS APPROVED	24	36	60
NEW MOLECULAR ENTITIES APPROVED:	0	0	0
AS THE ENTITY	0	0	0
AS A SALT, ESTER OR DERIVATIVE			
OF THE ENTITY	0	0	0

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.E., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

v

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL
ACETAMINOPHEN W/ CODEINE # 2
 AA LEMMON 300MG;30MG
TYLENOL W/ CODEINE NO. 3
 AA MCNEIL PHARM 300MG;30MG

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
 AA DURAMED PHARMS 300MG;15MG
 AA 300MG;30MG
 AA 300MG;60MG

>_ADD>
 >_ADD> AA PAPA-DEINE # 3 300MG;30MG
 >_ADD> AA VANGARD LABS/MHM 300MG;30MG
 >_ADD> PAPA-DEINE # 6 300MG;60MG
 >_ADD> AA VANGARD LABS/MHM 300MG;60MG

ACETAMINOPHEN; HYDROCODONE BITARTRATE (PAGE 3-2)

TABLET; ORAL
 >_ADD> MYCDDAPHEN
 >_ADD> AA BF ASCHER 300MG;2MG

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL
CODACET
 AA HALSEY DRUG 325MG;5MG
 /PERCOCET-6/
 PERCOCET

/ACETAMINOPHEN; PHENACETIN; PHENYLBUTANOLAMINE HYDROCHLORIDE/
 /PHENYLOXANINE CITRATE/ (PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, XODINATED, X-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION
 /RADIOXODINATED SERUM ALBUMIN (HUMAN) X-131/
 /MALLINCKRODT/ B-7-250, 343/ML

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
 NEOPHAN 6.5%
 CUTTER-VITRUM 6.52M

AMINOPHYLLINE (PAGE 3-8)

/100MG; ORAL/
 SOLUTION; ORAL
AMINOPHYLLINE
 AA BAY LABORATORIES 100MG/5ML
 AA ROXANE LABORATORIES 100MG/5ML

TABLET; ORAL
AMINOPHYLLINE
 BD BARR LABORATORIES 100MG
 BD 200MG
 AB VANGARD LABS/MHM 100MG
 AB 200MG

AMITRIPTYLINE HYDROCHLORIDE (PAGE 3-10)

TABLET; ORAL
AMITRIPTYLINE HCL
 >_ADD> AB DANBURY PHARMACAL 10MG
 >_ADD> AB 25MG
 >_ADD> AB 50MG
 >_ADD> AB 75MG
 >_ADD> AB 100MG
 >_ADD> AB 150MG

AMPHETAMINE SULFATE (PAGE 3-13)

/CAPSULE; CONTROLLED RELEASE; ORAL/
 /BENZEDRINE/
 /SKAF LABORATORIES/ 15MG

/TABLET; ORAL/
 /BENZEDRINE/
 /SKAF LABORATORIES/ 15MG
 /10MG/

AMPICILLIN TRIHYDRATE; PROBENECID (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL
POLYXILLIN-FRB
 AB BRISTOL LABS/B-M EQ 3.5GM BASE/ROT:1GM/ROT
PROBAMPACIN
 AB BIOCRRAFT LABS EQ 3.5GM BASE/ROT:1GM/ROT

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE (PAGE 3-16)
TABLET; ORAL
SONA COMPOUND W/ CODEINE
WALLACE PHARMS./C-M 325MG;200MG;16MG
ASPIRIN; HYDROCODONE BITARTRATE (PAGE 3-16)
TABLET; ORAL
VICOPIN
KNOLL PHARMACEUTICAL 500MG;5MG
ATACURATE BESILATE (PAGE 3-16)
INJECTABLE; INJECTION
BURROUGHS WELLCOME
TRACRUM
10MG/MLM
ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-17)
LIQUID; ORAL
/LONDAXITE/
/LORD LABORATORIES/
/0.025MG/5ML;0.5MG/5ML/
/AZURETIN/ (PAGE 3-18)
/BRANBLE; ORAL/
/DIAMONX BLUE/
/ER SQUIBB AND SONS / (EPR/PACKET/
BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)
TABLET; ORAL
PFIZER LABS/PFIZER
800MG
BACITRACIN (PAGE 3-18)
OINTMENT; OPHTHALMIC
BACTACIN PHARMACEUTICAL
AT
500 UNITS/5MG
BENTRORIDE (PAGE 3-19)
SOLUTION; ORAL
CHYMER
ORION LABORATORIES
500MG/7.5ML

ASPIRIN; BUTALBITAL (PAGE 3-15)

ADRIA LABORATORIES 650MG;50HGM

KODAL

TABLET; ORAL

AA

BUTALBITAL M/ ASPIRIN 325MG;40HGM

AA

BUTALBITAL M/ ASPIRIN 325MG;40HGM

AA

PURPAC/KALI PHARMA 325MG;40HGM

AA

BUTALBITAL M/ ASPIRIN AND CAFEINE

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN; BUTALBITAL; CAFEINE; PHENACETIN ((PAGE 3-15))

ASPIRIN; CAFEINE; DIHYDROCCODEINE BITARTATE (PAGE 3-15)

CAPSULE; ORAL

SYNLAGE-DC

IYES LABS/MHO

356.4MG;30MG;16HGM

(PAGE 3-15)

ASPIRIN; CAFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL

DARON COMBUND-65

EI LILLY INDSTRS./PR 325MG;32.4MG;65HGM

PROPOXYPHENE COMBUND 65

AA

LEMION

325MG;32.4MG;65HGM

AA

SKAF LABORATORIES 325MG;32.4MG;65HGM

ASPIRIN; CARISOPRODOL (PAGE 3-16)

TABLET; ORAL

SOMA COMBUND

MALLACE PHARM/C-M 325MG;20HGM

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL

> DLT > /BP/ /CORP. LABORATORIES/ /50MG/
> DLT > /BP/ /CORP. LABORATORIES/ /25MG/
> ADD > BP REID-PROVIDENT LABS 50MG
> ADD > /BP/ /CORP. LABORATORIES/ /25MG/
> ADD > /BP/ /CORP. LABORATORIES/ /25MG/
> ADD > /BP/ /CORP. LABORATORIES/ /25MG/

BENZTROPINE MESYLATE (PAGE 3-20)

TABLET; ORAL

BENZTROPINE MESYLATE
BP QUANTUM PHARMICS 0.5MG
BP 1MG
BP 2MG
COGENTIN
BP MSD/MERCK 0.5MG
BP 1MG
BP 2MG

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE

LOTION; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE
VALISONE
AB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE
VALISONE
AB SCHERING EQ 0.1% BASE

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE (PAGE 3-22)

SYRUP; ORAL

AMBENYL
HARION LABORATORIES 12.5MG/5ML;10MG/5ML

BROMPHENTRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL

BROMPHENTRAMINE MALEATE
/AA/ /POLAR PHARMACEUTICAL/ 4MG/

> ADD > BROMPHENTRAMINE MALEATE; CODEINE PHOSPHATE;
> ADD > PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-23)

> ADD > SYRUP; ORAL
> ADD > DIMETANE-DC
> ADD > AH ROBINS 2MG/5ML;10MG/5ML;12.5MG/5ML

> ADD > BROMPHENTRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE;
> ADD > PSEUDOEPHEDRINE HYDROCHLORIDE (PAGE 3-23)

> ADD > SYRUP; ORAL
> ADD > DIMETANE-DX
> ADD > AH ROBINS 2MG/5ML;10MG/5ML;30MG/5ML

> ADD > BROMPHENTRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
(PAGE 3-23)

> ADD > ELIXIR; ORAL
> ADD > ELIXIR DIMETAPP
> ADD > AH ROBINS 4MG/5ML;25MG/5ML

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION

MARCAINE SOL W/ EPINEPHRINE
AP BREON LABS/STERLING 0.5%:0.0021MG/ML
AP 0.75%:0.0021MG/ML
SENSORCAXE
AP ASTRA HOSP PHARM 0.5%:0.0021MG/ML
AP 0.75%:0.0021MG/ML

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION
SEFFIN
 AP GLAXO EQ 1GM BASE/VIALM
 AP EQ 2GM BASE/VIALM
 EQ 10GM BASE/VIALM

CEPHALOTHIN SODIUM; DEXTROSE (PAGE 3-31)

INJECTABLE; INJECTION
 CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
 TRAVENOL LABS EQ 20MG BASE/ML;50MG/MLM
 EQ 40MG BASE/ML;50MG/MLM

CEPHALOTHIN SODIUM; SODIUM CHLORIDE (PAGE 3-31)

INJECTABLE; INJECTION
 CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
 TRAVENOL LABS EQ 20MG BASE/ML;9MG/MLM
 EQ 40MG BASE/ML;9MG/MLM

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL
 LIBRELEASE
 HOFFMANN-LA ROCHE 30MG

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
 /AB/ /BOOTS PHARMACEUTICAL/ 5MG/
 /AB/ /10MG/
 /AB/ /25MG/

CHLOROPROCAINE HYDROCHLORIDE (PAGE 3-34)

INJECTABLE; INJECTION
 NESACAIN
 /PENNYWALT PHARM/ 11Z/
 12Z/
 ASTRA PHARM PRODS 1Z/
 2Z/
NESACAIN-CE
 /AB/ /PENNYWALT PHARM/ 12Z/
 /AB/ /32Z/
 /AB/ ASTRA PHARM PRODS 2Z/
 /AB/ 3Z/

CHLOROTHIAZIDE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE
 AB CHELSEA LABORATORIES 250MG
 AB 500MG

CHLOROTHIAZIDE; RESERPINE (PAGE 3-35)

TABLET; ORAL
 CHLOROTHIAZIDE AND RESERPINE
 BP 250MG;0.125MG
 BP WEST-WARD 500MG;0.125MG

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
 /AA/ /JONE PAULSEN/ /4MG/

CHLORPROPAMIDE (PAGE 3-36)

TABLET; ORAL
CHLORPROPAMIDE
 AB PAR PHARMACEUTICAL 100MG
 AB 250MG
DIABINSE
 AB PFIZER LABS/PFIZER 100MG

CHLORTHALIDONE (PAGE 3-36)

TABLET; ORAL
CHLORTHALIDONE
 AB PUREPAC/KALIPHARMA 50MG

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL
CHLORZOXAZONE
 AA PAR PHARMACEUTICAL 250MG

CHYMOPAPAIN (PAGE 3-39)

INJECTABLE; INJECTION
 DISCISE
 TRAVENOL LABS 12,500 UNITS/VIALM

AT BARNES-HIND PHARMS EQ 0.1% PHOSPHATE
AT PHARMALAIR EQ 0.1% PHOSPHATE
DEKATZ
SOLUTION/DROPS; OPTHALMIC
AP ORGANON/AKZONA EQ 4MG PHOSPHATE/ML
HEXADROL
AP INTL MEDICATION SYS EQ 20MG PHOSPHATE/ML
DEKAMETHASONE SODIUM PHOSPHATE
AP INVENEX LABS/DEXTER EQ 4MG PHOSPHATE/ML
DEKAMETHASONE
INJECTABLE; INJECTION
DEKAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)
BP BP
BP PAR PHARMACEUTICAL 6MG
DEKAMETHASONE
BP MSD/HERCK 6MG
DEKABRON
TABLET; ORAL
ROXANE LABORATORIES 0.5MG/0.5MLM
DEKAMETHASONE INTENSOL
ROXANE LABORATORIES 0.5MG/5MLM
DEKAMETHASONE
SOLUTION; ORAL
DEKAMETHASONE (PAGE 3-49)
HOECHST-ROUSSEL 0.25%
TOPICORT
OINTMENT; TOPICAL
DESOXIMETHASONE (PAGE 3-49)
BP BP
BP JACOBUS PHARM 25MG
DAPSONE
BP BP
BP KYROST LABS/AYNO/ 25MG
BP KYROST LABS/AYNO/ 100MG
TABLET; ORAL
DAPSONE (PAGE 3-47)

AA PIONEER PHARMS 4MG
CYPROHEPTADINE HCL
TABLET; ORAL
CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)
SANDAZ PHARMS/SANDAZ 100MG/MLM
SOLUTION; ORAL
SANDAZ PHARMS/SANDAZ 50MG/MLM
SANDIMUNE
INJECTABLE; INJECTION
CYCLOSPORINE (PAGE 3-46)
AP AP
AP PARKE DAVIS-W-L /6.3MG/ML/
EYISER
AP AP
AP MSD/HERCK /6.3MG/ML/
REDSOL
AP HAUERT BIOLOGICAL 3MG/MLM
BODENHIM
AP SOLOPAK/WPL 3MG/MLM
EYANOCOBALAMIN
INJECTABLE; INJECTION
CYANOCOBALAMIN (PAGE 3-44)
BP BP
BP HENH LABS/AYNO/ /40 UNITS/ML/
BP HENH LABS/AYNO/ /40 UNITS/ML/
INJECTABLE; INJECTION
CORTICOTROPIN
CORTICOTROPIN (PAGE 3-43)
LOTION; TOPICAL
SCHERING 1%
CLOTIRIMAZOLE (PAGE 3-41)
SKF LAB 400MG
TAGMET
TABLET; ORAL
CIMEIYDINE (PAGE 3-39)

DEXCHLORPHENIRAMINE MALEATE (PAGE 3-51)

SYRUP; ORAL
 > ADD > DAYLARAMINE
 > ADD > AA BAY LABORATORIES 2MG/5MLM
 > ADD > AA POLARAMINE
 SCHERING 2MG/5ML

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
 /DOPAMINE HCL IN DEXTROSE 5%/
 DOPAMINE HCL
 AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
 AP 5GM/100ML;160MG/100ML
 DOPAMINE HCL IN PLASTIC CONTAINER
 AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
 AP 5GM/100ML;160MG/100ML
 5GM/100ML;320MG/100ML

DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

INJECTABLE; INJECTION
 HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC
 CONTAINER
 TRAVENOL LABS 5GM/100ML;4,000 UNITS/100MLM

DEXTROSE; LIDOCAINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
 LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
 > ADD > AP AM MCGAW/AM HOSP 5GM/100ML;200MG/100ML
 LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
 > ADD > AP AM MCGAW/AM HOSP 5GM/100ML;400MG/100ML
 LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
 > ADD > AP AM MCGAW/AM HOSP 5GM/100ML;800MG/100ML

DIATRIZOATE MEGALUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION
 /DIATRIZOATE MEGALUMINE AND DIATRIZOATE SODIUM/
 DIATRIZOATE-60

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

TABLET; ORAL
DIETHYLPROPION HCL
 AA CAMALL 25MG

DIPHENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION
 DIPHENHYDRINATE
 /AA/ /INTL MEDICATION SYS//10MG/ML/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL
 /AA/ SK-DIPHENHYDRAMINE
 SK&F LABORATORIES //10MG/
 ELIXIR; ORAL
 BELTZ
 AA HALSEY DRUG 12.5MG/5MLM
 DIBENIL
 AA HR CENCI LABS 12.5MG/5MLM
 DIPHENHYDRAMINE HCL
 /AA/ /CORP. LABORATORIES/ //14.5MG/5ML/
 /SK-DIPHENHYDRAMINE/
 /AA/ /SK&F LABORATORIES/ //14.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL
 DISULFIRAM
 BX CHELSEA LABORATORIES 250MG
 BX 500MG
 BX SIDHAK LABORATORIES 250MG
 BX 500MG

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL
 DOXYCYCLINE HYCLATE
 AB CHELSEA LABORATORIES EQ 50MG BASE
 AB HEATHER DRUG EQ 50MG BASEM
 AB EQ 100MG BASEM
 AB PAR PHARMACEUTICAL EQ 100MG BASEM
 AB PUREPAC/KALIPHARMA EQ 50MG BASEM
 AB EQ 100MG BASEM

INJECTABLE; INJECTION
 DOXY 100
 AP LYPHO-MED EQ 100MG BASE/VIALM
 DOXY 200
 AP LYPHO-MED EQ 200MG BASE/VIALM
 DOXYCYCLINE
 AP ELKINS-SINN EQ 100MG BASE/VIALM
 AP EQ 200MG BASE/VIALM
 VIBRAMYCIN
 AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

FLUOXHYMESTERONE (PAGE 3-77)

TABLET; ORAL
FLUOXHYMESTERONE
BP BOLAR PHARMACEUTICAL 2MG#
BP 5MG#
BP 10MG#
BP COLMED LABORATORIES 10MG#

FOLIC ACID (PAGE 3-78)

TABLET; ORAL
FOLIC ACID
>_ADD> AA VANGARD LABS/MMM 1MG#

FUROSEMIDE (PAGE 3-79)

INJECTABLE; INJECTION
FUROSEMIDE
AP NATCON CHEMICAL 10MG/ML#

TABLET; ORAL
FUROSEMIDE
AB BARR LABORATORIES 60MG#
AB INTL MEDICATION SYS 20MG#
AB 60MG#
AB ROXANE LABORATORIES 20MG#
AB 60MG#
AB ZENITH LABORATORIES 20MG#
AB 60MG#

GENTAMICIN SULFATE (PAGE 3-79)

CREAM; TOPICAL
GENTAFATE
AT PHARMAFAIR EQ 1MG BASE/GM#
AT GENTAMICIN SULFATE
AT NMC LABORATORIES EQ 1MG BASE/GM#

INJECTABLE; INJECTION
GENTAMICIN SULFATE
AP ABBOTT LABORATORIES EQ 60MG BASE/100ML#
AP EQ 70MG BASE/100ML#
AP EQ 80MG BASE/100ML#
AP EQ 90MG BASE/100ML#
AP EQ 100MG BASE/100ML#
AP EQ 1.2MG BASE/ML#
AP EQ 1.4MG BASE/ML#
AP EQ 1.6MG BASE/ML#
AP EQ 1.8MG BASE/ML#
AP EQ 2MG BASE/ML#
AP EQ 10MG BASE/ML#
AP EQ 40MG BASE/ML#
AP EQ 40MG BASE/ML#
AP LYPHO-MED

GENTAMICIN SULFATE (PAGE 3-79)

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES EQ 60MG BASE/100ML#
AP EQ 70MG BASE/100ML#
AP EQ 80MG BASE/100ML#
AP EQ 90MG BASE/100ML#
AP EQ 100MG BASE/100ML#
AP EQ 1.2MG BASE/ML#
AP EQ 1.4MG BASE/ML#
AP EQ 1.6MG BASE/ML#
AP EQ 1.8MG BASE/ML#
AP EQ 2MG BASE/ML#

OINTMENT; TOPICAL
GENTAMICIN SULFATE
>_ADD> AT NMC LABORATORIES EQ 1MG BASE/GM#
AT THAMES PHARMACAL EQ 1MG BASE/GM#

SOLUTION/DROPS; OPHTHALMIC
GENTACIDIN
>_ADD> AT COOPERVISION PHARMS EQ 3MG BASE/ML#

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION
/ANTUITIN 6/
/AP/ /PARKE-DAVIS/N-L/ /6,000 UNITS/VIAL/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL
FULVICIN P/G 165
AB SCHERING 165MG
FULVICIN P/G 330
AB SCHERING 330MG
GRISACTIN ULTRA
AB AYERST LABS/AMHO 165MG#
AB 330MG#

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION
HEPARIN SODIUM
AP NATCON CHEMICAL 1,000 UNITS/ML#

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
AP ABBOTT LABORATORIES 10,000 UNITS/100ML; 450MG/100ML#

Original from
UNIVERSITY OF MICHIGAN

HYDROCORTISONE ACETATE (PAGE 3-93)

LOTION; TOPICAL
/HYDROCORTISONE ACETATE/
/AT/ /TOWNE, PAULSEN/ /0.12/
/SUSPENSION DROPS; OPHTH. ALIC./
/HYDROCORTISONE/
/HSPD, HEPER/ /2.52/

HYDROCORTISONE VALERATE (PAGE 3-95)

OINTMENT; TOPICAL
WESTCORT
WESTWOOD PHARMS 0.22M

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL
HYDROFLUMETHIAZIDE AND RESERPINE
BP COLMED LABORATORIES 50MG;0.125MG

HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)

INJECTABLE; INJECTION
DILAUDIO-HP
KNOLL PHARMACEUTICAL 10MG/MLM

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL
HYDROXYZINE HCL
AB BARR LABORATORIES 10MG
AB DANBURY PHARMACAL 10MG
AB 25MG
AB 50MG

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMOATE
AB DURAMED PHARMS EQ 25MG HCLM
AB EQ 50MG HCLM
AB EQ 100MG HCLM
AB VANGARD LABS/MMH EQ 25MG HCLM
AB EQ 50MG HCLM

IBUPROFEN (PAGE 3-97)

TABLET; ORAL
MOTRIN
> ADD > AB UPJOHN MANUFACTURING 600MG
RUFEN
> ADD > AB BOOTS PHARMACEUTICAL 600MG

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
/BP/ /ANTIPRESS/ /25MG/
/AB/ /LEMON/ /25MG/
/AB/ /MAVATE/ /25MG/
/AB/ /H. ROBINS/ /50MG/
IMIPRAMINE HCL
AB PAR PHARMACEUTICAL 10MG
AB 25MG
AB 50MG

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
> ADD > AM ARMOUR PHARM 0.1672M
> ADD > AM 0.22M
> ADD > AM 0.252M
AM INTL MEDICATION SYS 0.1672M
AM ROXANE LABORATORIES 0.1672M
> ADD > AM TRAVENOL LABS 0.142M
AM 0.252M

ISONIAZID (PAGE 3-101)

SYRUP; ORAL
ISONIAZID
AA CAROLINA MED PRODS 50MG/5MLM
RIMFON
AA HOFFMANN-LA ROCHE 50MG/5ML

ISOPROTERENOL HYDROCHLORIDE (PAGE 3-102)

SOLUTION; INHALATION
ISOPROTERENOL HCL
/AM/ /INTL MEDICATION SYS/ /0.12/

21

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
 AP G POHL-BOSKAMP 5MG/ML*
 1MG/ML*
TRIDIL
 AM CRITICAL CARE/AMS 0.5MG/ML*

NIYSTATIN (PAGE 3-129)

ointment; TOPICAL
NIYSTATIN
 AT CLAY-PARK LABS 100,000 UNITS/GM*
 POWDER; ORAL
 NIYSTAT
 LEDERLE LABS/AM CYAN 100%*

NIYSTATIN (PAGE 3-129)

TABLET; ORAL
NIYSTATIN
 AA PAR PHARMACEUTICAL 500,000 UNITS*
 TABLET; VAGINAL
NIYSTATIN
 AT E FOUGERA/BYK-GLDN 100,000 UNITS*
 AT PHARMADERM/BYK-GLDN 100,000 UNITS*

OXPRENOLOL HYDROCHLORIDE (PAGE 3-131)

CAPSULE; ORAL
 TRASICOR
 CIBA/CIBA-GEIGY 20MG*
 40MG*
 80MG*
 160MG*

OXTRIPHYLLINE (PAGE 3-131)

ELIXIR; ORAL
OXTRIPHYLLINE
 BAY LABORATORIES 100MG/5ML*

OXTRIPHYLLINE (PAGE 3-131)

SYRUP; ORAL
CHOLEDYL
 AA PARKE-DAVIS/W-L 50MG/5ML
OXTRIPHYLLINE PEDIATRIC
 AA BAY LABORATORIES 50MG/5ML*
 TABLET, ENTERIC COATED; ORAL
CHOLEDYL
 AB PARKE-DAVIS/W-L 100MG
 AB 200MG
OXTRIPHYLLINE
 AB SOLAR PHARMACEUTICAL 100MG*
 AB 200MG*

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL
OXLOPAR
 /AA/ /PARKE-DAVIS/W-L/ /EG 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL
UTICLIN V*
 /AA/ /DP/CHN/ /EG 125MG BASE/5ML/
 /AA/ /EG 250MG BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-136)

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
 AA FERDALE LABS 55MG*

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL
DAPEX-P
 AA LEMMON 37.5MG*
DAPEX-37.5
 AA FERDALE LABS 37.5MG*
PHENTERMINE HCL
 AA CAMALL 37.5MG*

PREDNISOLONE TEBUATE (PAGE 3-147)

INJECTABLE: INJECTION

BP HYDELTRA-TBA 20MG/ML

BP PREDNISOLONE TEBUATE 20MG/ML

BP CARTER-GLOBAU LABS 20MG/ML

PREDNISONE (PAGE 3-147)

TABLET: ORAL

PREDNISONE

BP DURAMED PHARMS 5MG

BP 10MG

BP 20MG

BP 5MG

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE: ORAL

PROCAN

BP PARKE-DAVIS-M-L 350MG

BP 500MG

PROPANTHELINE BROMIDE (PAGE 3-153)

TABLET: ORAL

PROPANTHELINE BROMIDE

BP PAR PHARMACEUTICAL 15MG

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE: ORAL

PROPOXYPHENE HCL

BP RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET: ORAL

PROPYLTHIOURACIL

BP /HYLAN PHARMS/ 50MG

POTASSIUM CHLORIDE (PAGE 3-143)

INJECTABLE: INJECTION

POTASSIUM CHLORIDE

BP TRAVENOL LABS

BP 440MG/ML

BP 300MG/ML

BP 200MG/ML

BP 100MG/ML

BP 50MG/ML

BP 25MG/ML

BP 12.5MG/ML

BP 6.25MG/ML

BP 3.125MG/ML

BP 1.5625MG/ML

BP 0.78125MG/ML

BP 0.390625MG/ML

BP 0.1953125MG/ML

BP 0.09765625MG/ML

BP 0.048828125MG/ML

BP 0.0244140625MG/ML

BP 0.01220703125MG/ML

BP 0.006103515625MG/ML

BP 0.0030517578125MG/ML

BP 0.00152587890625MG/ML

BP 0.000762939453125MG/ML

BP 0.0003814697265625MG/ML

BP 0.00019073486328125MG/ML

BP 9.536743E-05MG/ML

BP 4.768371E-05MG/ML

BP 2.384186E-05MG/ML

BP 1.192093E-05MG/ML

BP 5.96046E-06MG/ML

BP 2.98023E-06MG/ML

BP 1.49011E-06MG/ML

BP 7.45055E-07MG/ML

BP 3.72527E-07MG/ML

BP 1.86264E-07MG/ML

BP 9.3132E-08MG/ML

BP 4.6566E-08MG/ML

BP 2.3283E-08MG/ML

BP 1.16415E-08MG/ML

BP 5.82075E-09MG/ML

BP 2.91037E-09MG/ML

BP 1.45519E-09MG/ML

BP 7.27595E-10MG/ML

BP 3.63797E-10MG/ML

BP 1.81899E-10MG/ML

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
(PAGE 3-155)

SYRUP; ORAL
ACTAMIST
 AA HR CENCI LABS 30MG/5ML;1.25MG/5ML
 /AA/ PSEUDOEPHEDRINE
 /AA/ BAY LABORATORIES/ 30MG/5ML;1.25MG/5ML/
 /AA/ TRIACIN
 /AA/ NATL. PHARM. INF. BUREAU/ 30MG/5ML;1.25MG/5ML/
 /AA/ TRIPOSED
 AA HALSEY DRUG 30MG/5ML;1.25MG/5ML

TABLET; ORAL
 /AA/ Tri-sudo
 /AA/ MD PHARMACEUTICAL/ 60MG;2.5MG/
 /AA/ TRIPROLINE
 /AA/ DANBURY PHARMACAL/ 60MG;2.5MG/
 /AA/ TRIPROLIDINE AND PSEUDOEPHEDRINE
 AA SOLAR PHARMACEUTICAL 60MG;2.5MG
 /AA/ West-Adap
 /AA/ 60MG;2.5MG/
 /AA/ TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
 AA CHELSEA LABORATORIES 60MG;2.5MG

QUINIDINE GLUCONATE (PAGE 3-157)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
 AB ROXANE LABORATORIES 324MG

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
 AB VITARINE/WEST CHEM 300MG

RESERPINE (PAGE 3-158)

TABLET; ORAL
 /BP/ RAURINE
 /BP/ ONEAL JONES & FELLOMAN/ 0.25MG/
 /BP/ RESERPINE
 /BP/ CORP. LABORATORIES/ 0.25MG/
 /BP/ 0.25MG/
 /BP/ MYLAN PHARMS 0.25MG/
 /BP/ 0.25MG/
 > DLT > /BP/
 > DLT > /BP/

RESERPINE (PAGE 3-158)

TABLET; ORAL
 /BP/ NIO-SERPINE
 /BP/ ROWELL LABORATORIES/ 0.25MG/
 /BP/ 0.25MG/

SECOBARBITAL SODIUM (PAGE 3-160)

CAPSULE; ORAL
SECOBARBITAL SODIUM
 AA LANNETT 50MG
SECONAL SODIUM
 AA ELI LILLY 50MG
 AA 100MG

SELENIUM SULFIDE (PAGE 3-161)

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
 AT BAY LABORATORIES 2.52M

SILVER SULFADIAZINE (PAGE 3-161)

CREAM; TOPICAL
SILVER SULFADIAZINE
 SSD

SITOSTEROL ALPHA (PAGE 3-161)

/SUSPENSION; ORAL/
 /CITELLON/
 /ELI LILLY/ /BAY LILLY/

SODIUM CHLORIDE (PAGE 3-162)

INJECTABLE; INJECTION
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
 TRAVENOL LABS 36M/100ML
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
 TRAVENOL LABS 56M/100ML

SODIUM POLYSTYRENE SULFONATE (PAGE 3-165)

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
 AA ROXANE LABORATORIES 15GM/60ML
 SPS
 AA CAROLINA MED PRODS 15GM/60ML

SOMATROPIN (PAGE 3-165)

INJECTABLE; INJECTION
 ASELLACRIN 2
 SERONO LABS 2 IU/VIAL
 /ASELLACRIN/
 ASELLACRIN 10

UNIVERSITY OF MICHIGAN

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL

THIORIDAZINE HCL
AA CORD LABORATORIES 50MG/ML
AA 100MG/ML
AA NATL PHARM MFG/BARRE 100MG/ML

TABLET; ORAL

MELLARIL
AB SANDOZ PHARMS/SANDOZ 100MG
> ADD > AB 150MG
> ADD > AB 200MG
THIORIDAZINE HCL
AB BARR LABORATORIES 10MG
AB 15MG
AB 25MG
AB 50MG
AB 100MG
AB BOLAR PHARMACEUTICAL 10MG
AB 100MG
> ADD > AB 150MG
> ADD > AB 200MG
AB CORD LABORATORIES 10MG
AB 15MG
AB 25MG
AB 50MG
AB DANBURY PHARMACAL 10MG
AB 15MG
AB 25MG
AB 50MG
AB MYLAN PHARMS 100MG
AB PAR PHARMACEUTICAL 10MG
AB 15MG
AB 25MG
AB 50MG
AB 100MG
> ADD > AB ROXANE LABORATORIES 10MG
> ADD > AB 25MG
> ADD > AB 50MG
> ADD > AB WEST-WARD 10MG
> ADD > AB 15MG
> ADD > AB 25MG
> ADD > AB 50MG
AB ZENITH LABORATORIES 100MG

TIMLOL MALEATE (PAGE 3-179)

TABLET; ORAL

BLOCADREN
 MSD/MERCK 5MG

TRIAMCINOLONE (PAGE 3-180)

TABLET; ORAL

TRIAMCINOLONE
> DLT > BP/ MYLAN PHARMS /4MG/
> DLT > BP/ /8MG/

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

AEROSOL; INHALATION

ARISTOCORT
LEDERLE LABS/AM CYAN/0.25MG/INH
 AZHACORT
 WILLIAM H RORER 0.25MG/INH

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE
AT BAY LABORATORIES 0.025%
AT 0.1%
AT 0.5%
> ADD > AT TRIDERM
> ADD > AT DEL-RAY LABORATORIES 0.1%

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE
AT BAY LABORATORIES 0.025%
AT 0.1%
AT 0.5%

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-183)

TABLET; ORAL

TRIAZINE
TFP

TRIPLENNAMINE HYDROCHLORIDE (PAGE 3-185)

TABLET; ORAL

TRIPLENNAMINE HCL
AA /WEST-WARD/ /50MG/

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL

AB /GARD-SANDOZ/
AB /EIDER PHARMS/ /500MG/5ML/
AB /TRISEN/
AB /BEECHAM LABS/BEECHAM/ /500MG/5ML/
AB /TRISURET/
AB /REID-PROVIDENT LABS/ /500MG/5ML/

> DLT > /AMINOPHYLLINE PHENDIMETAZINE NACAPHEDEZINE HYDROCHLORIDE/
(PAGE AD2)

> DLT > /TABLET: ORAL/
> DLT > /ASCOTRINE/
> DLT > /SEARLE PHARMS/ /100mg; 250mg/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE
HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E (PAGE AD2)

INJECTABLE; INJECTION

MVC PLUS

ASCOT HOSP PHARMS 10MG/ML; 0.006MG/ML; 0.5 UGH/ML;
1.5MG/ML; 20 IU/ML; 0.04MG/ML;
4MG/ML; 0.4MG/ML; 0.36MG/ML;
0.3MG/ML; 330 IU/ML; 1 IU/ML

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL

DIPYRIDAMOLE

ASCOT HOSP PHARMS 50MG

DURAMED PHARMS 25MG

50MG

75MG

HALSEY DRUG 50MG

SUPERPHARM 50MG

ISOSORBIDE DINITRATE (PAGE AD5)

TABLET; ORAL

ISOSORBIDE DINITRATE

> ADD > BARR LABORATORIES 30MG

/METHANUROSTENOLONE/ (PAGE AD6)

/TABLET: ORAL/
/METHANUROSTENOLONE/
/PAR. PHARMACEUTICAL/ /2.5MG/
/5MG/

/BROMOPHTHAZINE NALCATE; PHENYLEPHEDRINE HYDROCHLORIDE;
/PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/ELIXIR: ORAL/
/ELIXIR DIMEETAP/
/AL. ROBINS/ /2mg; 5mg; 10mg; 25mg; 50mg/

/TABLET: CONTROLLED RELEASE: ORAL/
/DIMEETAP/
/AL. ROBINS/ /12mg; 15mg; 15mg/

/CARBAMPHEN EDCSYLATE; CHLORPHENIRAMINE NALCATE; ISOPROPANOL;
/ISOPROPE; PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/CAPSULE: CONTROLLED RELEASE: ORAL/
/TUSSE-ORNADE/
/SKF. LABORATORIES/ /20mg; 25mg; 2.5mg; 5mg/

/SOLUTION: ORAL/
/TUSSE-ORNADE/
/SKF. LABORATORIES/ /2mg; 5mg; 10mg; 25mg; 50mg; 75mg; 100mg; 150mg/

DICYCLOMINE HYDROCHLORIDE (PAGE AD3)

SYRUP; ORAL

BAYCICLOMINE

BAY LABORATORIES 10MG/5ML

